These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer.
    Author: Gridelli C, Pepe R, Palmeri S, Iacobelli S, Gentile M, Gebbia V, Garufi C, Airoma G, Palmieri G, Russo A.
    Journal: Cancer Chemother Pharmacol; 1991; 28(5):405-7. PubMed ID: 1655301.
    Abstract:
    A total of 72 patients with metastatic stage IV non-small-cell lung cancer (NSCLC) were treated with combination chemotherapy comprising the MEV regimen (mitomycin C, 8 mg/m2 given i.v. on day 1; etoposide, 100 mg/m2 given i.v. on days 1-3; and vindesine, 3 mg/m2 given i.v. on day 1; treatment repeated every 3 weeks). In 65 evaluable patients, the objective response rate was 37% (complete responses, 4.7%; partial responses, 32.3%). The median survival was 7.6 months for all patients. The treatment was very well tolerated. MEV proved to be an active and non-toxic regimen for the treatment of metastatic NSCLC.
    [Abstract] [Full Text] [Related] [New Search]